Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP203988.RAghRxpcl-M9ny_cyXiNGnFZt2pbLNxwIVEt5S9RGcsT4130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP203988.RAghRxpcl-M9ny_cyXiNGnFZt2pbLNxwIVEt5S9RGcsT4130_provenance.
• NP906911.RAxvFMMpNfbDZlk9CFcUd-f1bFvAjNhwa6wM0udblqNfI130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP906911.RAxvFMMpNfbDZlk9CFcUd-f1bFvAjNhwa6wM0udblqNfI130_provenance.
• NP590809.RAJ_9Y-zCjVD84O2bNxKqKhjA4LwZ3We8mwxTSufnJoTk130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP590809.RAJ_9Y-zCjVD84O2bNxKqKhjA4LwZ3We8mwxTSufnJoTk130_provenance.
• NP407929.RA2emThSPOmyqDHwmYdc6ahTGA0sTcKzWxtJdscpTKUsY130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP407929.RA2emThSPOmyqDHwmYdc6ahTGA0sTcKzWxtJdscpTKUsY130_provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP836333.RAxHiz9S2tpc9sQH99QISH7CdCUYPAws0LD8tfH0tMonM130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP836333.RAxHiz9S2tpc9sQH99QISH7CdCUYPAws0LD8tfH0tMonM130_provenance.
• NP836335.RAy_HnHoh0PgJw-s9okTxdhLQkQIP0YF1cU5Lbc4FSKEI130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP836335.RAy_HnHoh0PgJw-s9okTxdhLQkQIP0YF1cU5Lbc4FSKEI130_provenance.
• NP836338.RAZA2Vwrze6EoDNGDAjLJmCulsPhcDkZLpdzUcuUCR9Hw130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP836338.RAZA2Vwrze6EoDNGDAjLJmCulsPhcDkZLpdzUcuUCR9Hw130_provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP576954.RAGNbOn-OhiE4mBQvgyWOdLJfVElrzVpIN6zkv4KeovyQ130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP576954.RAGNbOn-OhiE4mBQvgyWOdLJfVElrzVpIN6zkv4KeovyQ130_provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP219162.RAkiRiCO3stjP8dFw_XtIrizEEjPR7wPUVcILEg9ntLks130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219162.RAkiRiCO3stjP8dFw_XtIrizEEjPR7wPUVcILEg9ntLks130_provenance.
• NP836334.RApvloyMJ8YcZ6JQVGQWRt3Ji9lUSTu1ltD_4u1dH6g74130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP836334.RApvloyMJ8YcZ6JQVGQWRt3Ji9lUSTu1ltD_4u1dH6g74130_provenance.
• NP836336.RAlTdANT4BWXIR-Ni8kmaVDvqN-xepbV_MAmkhr-Z9sfA130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP836336.RAlTdANT4BWXIR-Ni8kmaVDvqN-xepbV_MAmkhr-Z9sfA130_provenance.
• NP836337.RAisGLFOu0vrDS8JqZVVyqRXibp3XMIH6faN5CqgYJ22Q130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP836337.RAisGLFOu0vrDS8JqZVVyqRXibp3XMIH6faN5CqgYJ22Q130_provenance.
• NP836339.RApEEoRc-vWXLRjqtq2p7u3g_4d1ohPCu7VpIDC_dOA8c130_assertion description "[Here we review results of recent studies with first-generation JAK2 inhibitors in the treatment of MPN and second-generation ABL and Flt3 inhibitors in CML and AML, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP836339.RApEEoRc-vWXLRjqtq2p7u3g_4d1ohPCu7VpIDC_dOA8c130_provenance.